Engineered immune cells take on Hard-to-Treat blood cancers
NCT ID NCT06191887
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 35 times
Summary
This early-phase trial is testing a new type of CAR T-cell therapy called MC10029 for people with B-cell blood cancers that have returned or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them in the lab to target a protein called BAFFR on cancer cells, and infusing them back along with chemotherapy. The main goals are to find the safest dose and to watch for side effects in 27 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BAFFR-targeting CAR T cells (MC10029) with chemotherapy (fludarabine and cyclophosphamide)
What this could lead to
If it works, this could offer a new treatment option for patients with B-cell cancers that have come back or stopped responding to standard therapy.
What could go wrong
This is a very early (Phase 1) trial with only 27 participants, so it is mainly checking safety and dosing. The treatment may not work, and side effects like cytokine release syndrome or nervous system problems are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.